Novartis Stops Iscalimab Trial In Kidney Transplant Patients

by Vandana Singh, Benzinga Editor

September 3, 2021 7:09 AM | 1 min read | Make a Comment

Novartis AG NVS has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.

Posted In: Biotech News Health Care General Briefs kidney disease Phase 2 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.